About this event

  • Date and time Thu 11 Jul 2024 from 9:15am to 6:00pm
  • Location Royal Society of Medicine

Delve into the vast potential of cell and gene therapy at our exclusive event.

Join us as we bring together key experts, researchers, and industry leaders for an enriching dialogue that explores the ground-breaking advances and transformative approaches offered by gene therapies.

Our distinguished speakers will provide insights into the latest cutting-edge research, offering you an essential briefing into the revolutionary treatments shaping the future of healthcare.

You will have the opportunity to better understand the ethical considerations surrounding this rapidly advancing field and engage in thoughtful discussions about the responsible implementation of these treatments.

Gene therapy involves introducing, altering, or replacing genetic material within a person's cells to treat or prevent diseases. It is giving hope to patients with a variety of conditions, including genetic diseases, blood disorders and cancer, who previously had limited or no treatment options.

This event, therefore, will be relevant for professionals in many medical fields and across various career stages, as well as researchers, pharmaceutical and biotech professionals, patient advocates, ethicists, policy makers and healthcare providers.

You will be able to connect with like-minded professionals, researchers, and industry experts throughout the day.

By attending this conference, you will: 

  • Understand how the introduction of gene therapy has and is changing treatment and patient experience. 
  • Learn how gene therapy is being used - including treatments and how far along each treatment is for different diseases. 
  • Discover what is next for gene therapy and its future impact across the health service. 
  • Understand the issues facing the industry - the extreme costs of treatment and the challenges this causes for its delivery within the NHS. 

Don’t miss this unique opportunity to understand the challenges and opportunities for clinical practice created by this transformative research.

 

Follow us on: 
Facebook 
Instagram
LinkedIn
Twitter 
YouTube 

Show Virtual / In Person rates

Tickets (In Person)

Early Bird pricing available until 30 May 2024.

Member

RSM Fellow RSM Associate RSM Retired Fellow RSM Trainee RSM Student
£96.00 £57.00 £57.00 £45.00 £30.00

Non - Member

Consultant / GP / SAS Doctors Non Healthcare Professional AHP / Nurse / Midwife Trainee Student
£176.00 £150.00 £105.00 £105.00 £55.00

Tickets (Virtual)

Early Bird pricing available until 30 May 2024.

Member

RSM Fellow RSM Associate RSM Retired Fellow RSM Trainee RSM Student
£64.00 £38.00 £38.00 £30.00 £20.00

Non - Member

Consultant / GP / SAS Doctors Non Healthcare Professional AHP / Nurse / Midwife Trainee Student
£118.00 £100.00 £70.00 £70.00 £37.00

Key speakers

Mr John James OBE

Mr John James OBE

Chief Executive Officer (CEO), Sickle Cell Society

Speaker's biography

John James is the Chief Executive of the Sickle Cell Society (SCS), a role which he has held since 2013. Prior to working at SCS, John spent 33 years working in the NHS including as Chief Executive of NHS Trusts and in health policy as a senior civil servant for the Department of Health and Social Care. During his time as Chief Executive of SCS, the organisation has published several reports highlighting the impact of sickle cell disease on patients and has been instrumental in the publishing of national clinical standards and guidelines. In June 2018, John was awarded an OBE as part of the Queen’s Birthday Honours. John has been a member of the King’s Fund General Advisory Council since January 2021. 

Dr Sam Roberts

Dr Sam Roberts

Chief Executive Officer (CEO), National Institute of Health and Care Excellence (NICE)

Speaker's biography

Sam Roberts is the Chief Executive of the National Institute for Health and Care Excellence. She has worked in healthcare for 20 years in a combination of clinical, operational, private sector and academic roles. She originally trained as a doctor before undertaking an MBA and joining McKinsey and Company. Her focus for the last 15 years has been on improving quality of clinical care and supporting uptake of innovation - as Head of Operations at a large teaching hospital in London (UCLH), Director of Innovation, Research and Life Sciences at NHS England and Improvement and Chief Executive of the Accelerated Access Collaborative.

 

Prior to joining NICE she invested in early stage digital health and diagnostics companies. She has an academic interest in the influence of health economic analysis on policy and clinical practice, having worked at the London School of Economics followed by doctoral studies at the University of Oxford.  

Agenda

View the provisional programme

Registration, tea and coffee
Welcome and introduction

Professor Gillian Leng CBE, Dean of Education and President-Elect, Royal Society of Medicine 

Session 1: An introduction to gene therapies and ATMPs

What is the potential for cell and gene therapy?

Professor Uta Griesenbach, Professor of Molecular Medicine, National Heart and Lung Institute, Imperial College London and Past President, British Society for Gene and Cell Therapy

What is happening around the world?
How is gene therapy being used for acute and chronic conditions?

Mr John James OBE, Chief Executive Officer, Sickle Cell Society

Panel discussion

Chair: Professor Gillian Leng CBE, Dean and President Elect, Royal Society of Medicine

Panel: Professor Uta Griesenbach, Mr John James OBE

Lunch

Session 2: Navigating the future of gene therapy and ATMPs

What’s on the horizon?
How does this translate to day-to-day clinical practice?
How gene therapy development is shaping future of practice and where do we go from here?
Panel discussion

Chair: Professor Neil Watson, Co-Director, Northern Alliance Advanced Therapies Treatment Centre, Clinical Director of Pharmacy and Medicines Optimisation, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Professor of Practice, Faculty of Medical Sciences, Newcastle University

Tea and coffee break

Session 3: Ethical considerations of ATMPS and gene therapy in practice

Patient keynote

Ms Samantha Barber, Chief Executive Officer, Gene People

Drug regulations and standards

Dr Sam Roberts, Chief Executive Officer, National Institute for Health and Care Excellence (NICE)

Panel discussion

Chair: Professor Neil Watson

Panel: Ms Samantha Barber, Dr Sam Roberts

Tea and coffee break

Session 4: Panel discussion

Panel discussion

Chair: Professor Gillian Leng

Panel: Mr John James OBE, Dr Sam Roberts

Closing remarks
Close of event

Location

Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom

 

Registration for this event will close at 1:00am on Wednesday 10 July 2024. Late registrations will not be accepted.

The agenda is subject to change at any time

If the event is recorded, we are only able to share presentations that we have received permission to share. There is no guarantee that all sessions will be available after the event, this is at the presenter’s and RSM’s discretion.

All views expressed at this event are of the speakers themselves and not of the Royal Society of Medicine, nor the speaker's organisations.

This event will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.

If you are interested in supporting this conference, please contact our sponsorship team at sponsorship@rsm.ac.uk

Domus - reception

While you’re attending this event

Why not stay in the comfort of our hotel, Domus Medica, book dinner in the restaurant, or even hire one of our private dining rooms to socialise with your peers?

RSM members enjoy access to our enviable club facilities. For more information, please contact our team at domus@rsm.ac.uk or restaurant@rsm.ac.uk.

Find out more